685853-98-9

Basic information

• Product Name: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE
• Synonyms: OTAVA-BB BB7110952507;AURORA 23302;2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE;2-(4-METHYLPIPERAZINO)-5-(TRIFLUOROMETHYL)ANILINE;2-(4-METHYLPIPERAZINO)-5-(TRIFLUOROMETHYL)PHENYLAMINE;AKOS B033299
• CAS NO: 685853-98-9
• Molecular Formula: C₁₂H₁₆F₃N₃
• Molecular Weight: 259.27
• Mol File: 685853-98-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(685853-98-9)
• EPA Substance Registry System: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(685853-98-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 685853-98-9(Hazardous Substances Data)

Usage

General Description

The chemical 2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)aniline, also known as TAK-901, is a novel and potent small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) kinases. It acts as an anti-cancer agent by inhibiting the activation of the IGF-1R and IR signaling pathways, which are implicated in the growth and survival of tumor cells. TAK-901 has shown promising anti-tumor activity in preclinical studies and is being investigated for the treatment of various types of cancer, including breast, lung, and prostate cancer. Its unique chemical structure and mechanism of action make it a potential candidate for the development of new cancer therapeutics.

Upstream product

• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 109-01-3 1-methyl-piperazine 
• 315239-67-9 1-methyl-4-(2-nitro-4-trifluoromethyl-phenyl)-piperazine 

Downstream Products

• 1309358-91-5 N-[2-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]-1-phenylcyclo-propanecarboxamide 
• 926036-45-5 N-(2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 

Relevant articles and documents

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Novel pyrazole amide compound and preparation thereof, and application of novel pyrazole amide compound in prevention and treatment of plant pathogenic diseases and pest killing

The invention relates to a novel pyrazole amide compound I and a preparation method thereof and application of the novel pyrazole amide compound I in prevention and treatment of plant pathogenic disease and pest killing. The novel pyrazole amide compound

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase

The recognition that aberrant angiogenesis contributes to the pathology of inflammatory diseases, cancer, and myocardial ischemia has generated considerable interest in the molecular mechanisms that regulate blood vessel growth. The receptor tyrosine kinase Tie-2 is expressed primarily by vascular endothelial cells and is critical for embryonic vasculogenesis. Interference with the Tie-2 pathway by diverse blocking agents such as soluble Tie-2 receptors, anti-Tie-2 intrabodies, anti-Ang-2 antibodies, and peptide-F c conjugates has been shown to suppress tumor growth in xenograft studies. An alternative strategy for interfering with the Tie-2 signaling pathway involves direct inhibition of the kinase functions of the Tie-2 receptor. Herein we describe the development of alkynylpyrimidine amide derivatives as potent, selective, and orally available ATP-competitive inhibitors of Tie-2 autophosphorylation.